Exploration of the ocular surface infection by SARS-CoV-2 and implications for corneal donation: An ex vivo study.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
03 2022
Historique:
received: 01 06 2021
accepted: 19 01 2022
entrez: 1 3 2022
pubmed: 2 3 2022
medline: 12 3 2022
Statut: epublish

Résumé

The risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission through corneal graft is an ongoing debate and leads to strict restrictions in corneas procurement, leading to a major decrease in eye banking activity. The aims of this study are to specifically assess the capacity of human cornea to be infected by SARS-CoV-2 and promote its replication ex vivo, and to evaluate the real-life risk of corneal contamination by detecting SARS-CoV-2 RNA in corneas retrieved in donors diagnosed with Coronavirus Disease 2019 (COVID-19) and nonaffected donors. To assess the capacity of human cornea to be infected by SARS-CoV-2, the expression pattern of SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE-2) and activators TMPRSS2 and Cathepsins B and L in ocular surface tissues from nonaffected donors was explored by immunohistochemistry (n = 10 corneas, 78 ± 11 years, 40% female) and qPCR (n = 5 corneas, 80 ± 12 years, 40% female). Additionally, 5 freshly excised corneas (80 ± 12 years, 40% female) were infected ex vivo with highly concentrated SARS-CoV-2 solution (106 median tissue culture infectious dose (TCID50)/mL). Viral RNA was extracted from tissues and culture media and quantified by reverse transcription quantitative PCR (RT-qPCR) (viral RNA copies) 30 minutes (H0) and 24 hours (H24) after infection. To assess the risk of corneal contamination by SARS-CoV-2, viral RNA was tested by RT-qPCR (Ct value) in both corneas and organ culture media from 14 donors diagnosed with COVID-19 (74 ± 10 years, 29% female) and 26 healthy donors (79 ± 13 years, 57% female), and in organ culture media only from 133 consecutive nonaffected donors from 2 eye banks (73 ± 13 years, 29% female). The expression of receptor and activators was variable among samples at both protein and mRNA level. Based on immunohistochemistry findings, ACE-2 was localized mainly in the most superficial epithelial cells of peripheral cornea, limbus, and conjunctiva, whereas TMPRSS2 was mostly expressed in all layers of bulbar conjunctiva. A significant increase in total and positive strands of IP4 RNA sequence (RdRp viral gene) was observed from 30 minutes to 24 hours postinfection in central cornea (1.1 × 108 [95% CI: 6.4 × 107 to 2.4 × 108] to 3.0 × 109 [1.4 × 109 to 5.3 × 109], p = 0.0039 and 2.2 × 107 [1.4 × 107 to 3.6 × 107] to 5.1 × 107 [2.9 × 107 to 7.5 × 107], p = 0.0117, respectively) and in corneoscleral rim (4.5 × 109 [2.7 × 109 to 9.6 × 109] to 3.9 × 1010 [2.6 × 1010 to 4.4 × 1010], p = 0.0039 and 3.1 × 108 [1.2 × 108 to 5.3 × 108] to 7.8 × 108 [3.9 × 108 to 9.9 × 108], p = 0.0391, respectively). Viral RNA copies in ex vivo corneas were highly variable from one donor to another. Finally, viral RNA was detected in 3 out of 28 corneas (11%) from donors diagnosed with COVID-19. All samples from the 159 nonaffected donors were negative for SARS-CoV-2 RNA. The main limitation of this study relates to the limited sample size, due to limited access to donors diagnosed with COVID-19 and concomitant decrease in the procurement corneas from nonaffected donors. In this study, we observed the expression of SARS-CoV-2 receptors and activators at the human ocular surface and a variable increase in viral RNA copies 24 hours after experimental infection of freshly excised human corneas. We also found viral RNA only in a very limited percentage of donors with positive nasopharyngeal PCR. The low rate of positivity in donors diagnosed with COVID-19 calls into question the utility of donor selection algorithms. Agence de la Biomédecine, PFS-20-011 https://www.agence-biomedecine.fr/.

Sections du résumé

BACKGROUND
The risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission through corneal graft is an ongoing debate and leads to strict restrictions in corneas procurement, leading to a major decrease in eye banking activity. The aims of this study are to specifically assess the capacity of human cornea to be infected by SARS-CoV-2 and promote its replication ex vivo, and to evaluate the real-life risk of corneal contamination by detecting SARS-CoV-2 RNA in corneas retrieved in donors diagnosed with Coronavirus Disease 2019 (COVID-19) and nonaffected donors.
METHODS AND FINDINGS
To assess the capacity of human cornea to be infected by SARS-CoV-2, the expression pattern of SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE-2) and activators TMPRSS2 and Cathepsins B and L in ocular surface tissues from nonaffected donors was explored by immunohistochemistry (n = 10 corneas, 78 ± 11 years, 40% female) and qPCR (n = 5 corneas, 80 ± 12 years, 40% female). Additionally, 5 freshly excised corneas (80 ± 12 years, 40% female) were infected ex vivo with highly concentrated SARS-CoV-2 solution (106 median tissue culture infectious dose (TCID50)/mL). Viral RNA was extracted from tissues and culture media and quantified by reverse transcription quantitative PCR (RT-qPCR) (viral RNA copies) 30 minutes (H0) and 24 hours (H24) after infection. To assess the risk of corneal contamination by SARS-CoV-2, viral RNA was tested by RT-qPCR (Ct value) in both corneas and organ culture media from 14 donors diagnosed with COVID-19 (74 ± 10 years, 29% female) and 26 healthy donors (79 ± 13 years, 57% female), and in organ culture media only from 133 consecutive nonaffected donors from 2 eye banks (73 ± 13 years, 29% female). The expression of receptor and activators was variable among samples at both protein and mRNA level. Based on immunohistochemistry findings, ACE-2 was localized mainly in the most superficial epithelial cells of peripheral cornea, limbus, and conjunctiva, whereas TMPRSS2 was mostly expressed in all layers of bulbar conjunctiva. A significant increase in total and positive strands of IP4 RNA sequence (RdRp viral gene) was observed from 30 minutes to 24 hours postinfection in central cornea (1.1 × 108 [95% CI: 6.4 × 107 to 2.4 × 108] to 3.0 × 109 [1.4 × 109 to 5.3 × 109], p = 0.0039 and 2.2 × 107 [1.4 × 107 to 3.6 × 107] to 5.1 × 107 [2.9 × 107 to 7.5 × 107], p = 0.0117, respectively) and in corneoscleral rim (4.5 × 109 [2.7 × 109 to 9.6 × 109] to 3.9 × 1010 [2.6 × 1010 to 4.4 × 1010], p = 0.0039 and 3.1 × 108 [1.2 × 108 to 5.3 × 108] to 7.8 × 108 [3.9 × 108 to 9.9 × 108], p = 0.0391, respectively). Viral RNA copies in ex vivo corneas were highly variable from one donor to another. Finally, viral RNA was detected in 3 out of 28 corneas (11%) from donors diagnosed with COVID-19. All samples from the 159 nonaffected donors were negative for SARS-CoV-2 RNA. The main limitation of this study relates to the limited sample size, due to limited access to donors diagnosed with COVID-19 and concomitant decrease in the procurement corneas from nonaffected donors.
CONCLUSIONS
In this study, we observed the expression of SARS-CoV-2 receptors and activators at the human ocular surface and a variable increase in viral RNA copies 24 hours after experimental infection of freshly excised human corneas. We also found viral RNA only in a very limited percentage of donors with positive nasopharyngeal PCR. The low rate of positivity in donors diagnosed with COVID-19 calls into question the utility of donor selection algorithms.
TRIAL REGISTRATION
Agence de la Biomédecine, PFS-20-011 https://www.agence-biomedecine.fr/.

Identifiants

pubmed: 35231027
doi: 10.1371/journal.pmed.1003922
pii: PMEDICINE-D-21-02421
pmc: PMC8887728
doi:

Substances chimiques

Culture Media 0
RNA, Viral 0
Receptors, Coronavirus 0
Cathepsins EC 3.4.-
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Serine Endopeptidases EC 3.4.21.-
TMPRSS2 protein, human EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003922

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
J Clin Virol. 2021 Aug;141:104878
pubmed: 34134035
Lancet Infect Dis. 2020 Apr;20(4):411-412
pubmed: 32105638
Br J Ophthalmol. 2022 Mar;106(3):312-318
pubmed: 33243832
J Med Virol. 2020 Oct;92(10):2081-2086
pubmed: 32374427
Cornea. 2020 Dec;39(12):1556-1562
pubmed: 32826650
Curr Ophthalmol Rep. 2021;9(3):77-82
pubmed: 34377601
Ocul Surf. 2021 Jan;19:322-329
pubmed: 33176215
JAMA Ophthalmol. 2021 Apr 1;139(4):383-388
pubmed: 33475692
Cell Rep. 2020 Nov 3;33(5):108339
pubmed: 33147451
Eye (Lond). 2020 Jul;34(7):1206-1211
pubmed: 32424327
JAMA Ophthalmol. 2016 Feb;134(2):167-73
pubmed: 26633035
Cornea. 2021 Mar 1;40(3):342-347
pubmed: 32604196
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
J Strength Cond Res. 2013 Aug;27(8):2323-37
pubmed: 23880657
Nat Commun. 2020 Sep 2;11(1):4400
pubmed: 32879306
N Engl J Med. 1979 Mar 15;300(11):603-4
pubmed: 368632
Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1757-61
pubmed: 11431439
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Lancet. 2020 Feb 22;395(10224):e39
pubmed: 32035510
Exp Eye Res. 2003 Oct;77(4):515-24
pubmed: 12957150
Ocul Surf. 2021 Jan;19:190-200
pubmed: 32502616
Exp Eye Res. 2015 May;134:39-46
pubmed: 25795052
Ocul Surf. 2020 Oct;18(4):537-544
pubmed: 32544566
SSRN. 2020 Jul 15;:3650574
pubmed: 32742243
Cornea. 1997 Mar;16(2):132-7
pubmed: 9071524
Mol Syst Biol. 2020 Jul;16(7):e9610
pubmed: 32715618
Eye (Lond). 2004 May;18(5):519-24
pubmed: 15131685
Nature. 2015 May 21;521(7552):274-6
pubmed: 25993940
PLoS Comput Biol. 2020 Dec 8;16(12):e1008461
pubmed: 33290397
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Mol Cell Proteomics. 2020 Sep;19(9):1503-1522
pubmed: 32591346
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
Ophthalmology. 2021 Apr;128(4):494-503
pubmed: 32882309
Graefes Arch Clin Exp Ophthalmol. 2003 Nov;241(11):934-42
pubmed: 14586591
Diagnostics (Basel). 2021 Feb 21;11(2):
pubmed: 33670020
Lancet Microbe. 2020 May;1(1):e14-e23
pubmed: 32835326

Auteurs

Corantin Maurin (C)

Laboratory "Biology, engineering and imaging of Corneal Graft" BiiGC, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.

Zhiguo He (Z)

Laboratory "Biology, engineering and imaging of Corneal Graft" BiiGC, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.

Marielle Mentek (M)

Laboratory "Biology, engineering and imaging of Corneal Graft" BiiGC, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.

Paul Verhoeven (P)

CIRI, Centre International de Recherche en Infectiologie, GIMAP Team University of Lyon, University of St-Etienne, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL1, St-Etienne, France.
Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France.

Sylvie Pillet (S)

CIRI, Centre International de Recherche en Infectiologie, GIMAP Team University of Lyon, University of St-Etienne, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL1, St-Etienne, France.
Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France.

Thomas Bourlet (T)

CIRI, Centre International de Recherche en Infectiologie, GIMAP Team University of Lyon, University of St-Etienne, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL1, St-Etienne, France.
Laboratory of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne, France.

Françoise Rogues (F)

Hospital coordination of organ and/or tissue retrieval, University Hospital, Saint-Etienne, France.

Jean Loup Pugniet (JL)

Hospital coordination of organ and/or tissue retrieval, University Hospital, Saint-Etienne, France.

Thierry Peyragrosse (T)

Hospital coordination of organ and/or tissue retrieval, University Hospital, Saint-Etienne, France.

Marion Barallon (M)

Hospital coordination of organ and/or tissue retrieval, University Hospital, Saint-Etienne, France.

Chantal Perrache (C)

Laboratory "Biology, engineering and imaging of Corneal Graft" BiiGC, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.

Inès Aouimeur (I)

Laboratory "Biology, engineering and imaging of Corneal Graft" BiiGC, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.

Sophie Acquart (S)

Eye bank, French Blood Center, Saint-Etienne, France.

Sandrine Ninotta (S)

Eye bank, French Blood Center, Saint-Etienne, France.

Marc Baud'huin (M)

Nantes Université, CHU Nantes, Banque Muti-Tissus, Nantes, France.

Bertrand Vabres (B)

Nantes Université, CHU Nantes, Banque Muti-Tissus, Nantes, France.
Nantes Université, CHU Nantes, Service Ophthalmologic, Nantes, France.

Sylvain Poinard (S)

Laboratory "Biology, engineering and imaging of Corneal Graft" BiiGC, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.
Ophthalmology Department, University Hospital, Saint-Etienne, France.

Philippe Gain (P)

Laboratory "Biology, engineering and imaging of Corneal Graft" BiiGC, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.
Ophthalmology Department, University Hospital, Saint-Etienne, France.

Gilles Thuret (G)

Laboratory "Biology, engineering and imaging of Corneal Graft" BiiGC, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.
Ophthalmology Department, University Hospital, Saint-Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH